COMMUNIQUÉS West-GlobeNewswire

-
Cannabis: The Gateway to Tomatoes? New Survey Says Yes
06/08/2025 -
Extendicare Announces 2025 Second Quarter Results
06/08/2025 -
NADP Foundation Issues Request for Proposals
06/08/2025 -
Immix Biopharma Announces Other Serious Diseases Strategy
06/08/2025 -
ONWARD Medical annonce la nomination de Lucas Buchanan à son conseil d’administration
06/08/2025 -
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
06/08/2025 -
Profusa, Inc. Provides Strategy Overview and Business Update for Investors
06/08/2025 -
Lung Health Foundation Encouraged by Ontario’s $1.8 Billion Primary Care Investment and Hopes Vital Respiratory Services Will Be Included
06/08/2025 -
Milestone Scientific Appoints Jason Papes as Senior Vice President, Global Head of Sales and Marketing
06/08/2025 -
Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology
06/08/2025 -
RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire
06/08/2025 -
Intelligent Bio Solutions Strengthens FDA 510(k) Package with New Cybersecurity and Performance Data Ahead of Planned U.S. Market Launch
06/08/2025 -
Veru Announces Reverse Stock Split
06/08/2025 -
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
06/08/2025 -
Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering
06/08/2025 -
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
06/08/2025 -
SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)
06/08/2025 -
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
06/08/2025 -
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
06/08/2025
Pages